文献速递贫血与红细胞疾病血栓与止血

免疫检查点抑制剂的血液学并发症

Hematologic complications of immune checkpoint inhibitors.
PubMed 文献 · Blood · 2022-01-01

本文综述了免疫检查点抑制剂(ICI)相关血液学毒性的临床与病理生理框架。ICI通过过度活跃T淋巴细胞、自身抗体产生和/或细胞因子失调引起免疫相关不良效应。血液学毒性罕见且机制不明,管理常借鉴自身免疫性溶血性贫血、免疫性血小板减少症和特发性再生障碍性贫血的经验,需兼顾肿瘤治疗与血液毒性。

要点

  • ICI相关血液学毒性罕见且机制不明,管理借鉴已知免疫性血细胞减少症经验。
  • 管理需同时关注血液学毒性与恶性肿瘤,尽可能维持或最少中断有效抗癌治疗。
  • 目前7种ICI获FDA批准用于14种实体瘤和2种血液恶性肿瘤。

核心结论

  • ICI相关血液学毒性罕见且机制不确定,管理基于类似免疫性血细胞减少症的经验,需平衡血液学毒性与肿瘤治疗。

研究设计与样本

  • 综述,总结ICI相关血液学毒性的临床与病理生理框架,未报告系统检索范围或样本量。

主要发现

  • ICI通过过度活跃T淋巴细胞、自身抗体产生和/或细胞因子失调引起免疫相关不良效应。
  • 血液学毒性罕见,机制不确定。
  • 目前7种ICI获美国FDA批准,用于14种实体瘤和2种血液恶性肿瘤。

临床怎么用

  • 管理需同时关注血液学毒性与恶性肿瘤,尽可能维持或最少中断有效抗癌治疗。
  • 可借鉴自身免疫性溶血性贫血、免疫性血小板减少症和特发性再生障碍性贫血的管理经验。

局限性

  • 血液学毒性罕见且机制不确定,管理经验多来自类似免疫性疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors are a class of antineoplastic therapies that unleash immune cells to kill malignant cells. There are currently 7 medications that have been approved by the US Food and Drug Administration for the treatment of 14 solid tumors and 2 hematologic malignancies. These medications commonly cause immune-related adverse effects as a result of overactive T lymphocytes, autoantibody production, and/or cytokine dysregulation. Hematologic toxicities are rare and of uncertain mechanism, and therefore management is often based on experiences with familiar conditions involving these perturbed immune responses, such as autoimmune hemolytic anemia, immune thrombocytopenia, and idiopathic aplastic anemia. Management is challenging because one must attend to the hematologic toxicity while simultaneously attending to the malignancy, with the imperative that effective cancer therapy be maintained or minimally interrupted if possible. The purpose of this review is to help clinicians by providing a clinical and pathophysiological framework in which to view these problems.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kroll MH, Rojas-Hernandez C, Yee C, et al. Hematologic complications of immune checkpoint inhibitors. Blood. 2022. PMID: 34610113. doi:10.1182/blood.2020009016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。